Bayforest Capital Ltd Acquires 5,067 Shares of Insmed, Inc. $INSM

Key Points

• Bayforest Capital Ltd increased its stake in Insmed, Inc. by 255.0%, owning 7,054 shares valued at approximately $538,000.
• Insmed reported a loss of $1.70 EPS for the last quarter, missing estimates, but had an annual revenue increase of 18.9%.
• Several analysts have raised their price targets for Insmed, with an average target of $139.86 and a rating of "Moderate Buy."

Bayforest Capital Ltd boosted its holdings in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 255.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,054 shares of the biopharmaceutical company's stock after purchasing an additional 5,067 shares during the period. Bayforest Capital Ltd's holdings in Insmed were worth $538,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Cullen Frost Bankers Inc. raised its position in shares of Insmed by 164.9% in the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 221 shares in the last quarter. Elequin Capital LP acquired a new stake in shares of Insmed in the 4th quarter valued at about $28,000. NBC Securities Inc. acquired a new stake in shares of Insmed in the 1st quarter valued at about $49,000. Versant Capital Management Inc grew its stake in shares of Insmed by 546.3% in the 1st quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company's stock valued at $53,000 after buying an additional 590 shares during the period. Finally, Signaturefd LLC grew its stake in shares of Insmed by 60.0% in the 1st quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company's stock valued at $66,000 after buying an additional 325 shares during the period.

Insider Buying and Selling

In related news, CEO William Lewis sold 6,865 shares of the company's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $128.40, for a total value of $881,466.00. Following the completion of the transaction, the chief executive officer directly owned 233,924 shares in the company, valued at approximately $30,035,841.60. The trade was a 2.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Melvin Md Sharoky sold 10,000 shares of the company's stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $129.50, for a total transaction of $1,295,000.00. Following the completion of the transaction, the director owned 274,516 shares of the company's stock, valued at $35,549,822. This trade represents a 3.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 248,577 shares of company stock valued at $27,137,914 in the last three months. 3.00% of the stock is owned by corporate insiders.

Insmed Price Performance

Shares of INSM traded down $3.96 during mid-day trading on Monday, reaching $141.98. 968,195 shares of the stock traded hands, compared to its average volume of 2,759,076. The firm has a fifty day moving average price of $119.40 and a 200 day moving average price of $92.09. The company has a market cap of $30.01 billion, a price-to-earnings ratio of -24.88 and a beta of 0.97. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $149.08.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). The firm had revenue of $107.42 million for the quarter, compared to analysts' expectations of $104.06 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The firm's revenue for the quarter was up 18.9% on a year-over-year basis. During the same quarter last year, the firm earned ($1.94) earnings per share. Insmed has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on INSM shares. Wells Fargo & Company boosted their target price on Insmed from $140.00 to $171.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 3rd. JPMorgan Chase & Co. boosted their target price on Insmed from $111.00 to $135.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 20th. Jefferies Financial Group boosted their target price on Insmed from $129.00 to $148.00 and gave the stock a "buy" rating in a research note on Wednesday, August 13th. Morgan Stanley boosted their target price on Insmed from $126.00 to $144.00 and gave the stock an "equal weight" rating in a research note on Thursday, August 21st. Finally, The Goldman Sachs Group lifted their price target on shares of Insmed from $114.00 to $142.00 and gave the stock a "buy" rating in a report on Wednesday, August 13th. Sixteen research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $139.86.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.